Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
Autor: | Amanda Yu, Naveed Z. Janjua, Alnoor Ramji, Eric M. Yoshida, Hasina Samji, María José Pérez Álvarez, Carmine Rossi, Mel Krajden, Stanley Wong, Darrel Cook, Zahid A Butt, Nuria Chapinal, Mei Chong, Maryam Darvishian, Mark W. Tyndall |
---|---|
Rok vydání: | 2019 |
Předmět: |
Ledipasvir
medicine.medical_specialty animal structures Prescription drug Sofosbuvir Hepatitis C virus Population medicine.disease_cause Sofosbuvir/velpatasvir 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine otorhinolaryngologic diseases medicine 030212 general & internal medicine education Hepatitis education.field_of_study Hepatology business.industry fungi virus diseases food and beverages Original Articles medicine.disease 3. Good health chemistry Cohort Original Article 030211 gastroenterology & hepatology business medicine.drug |
Zdroj: | Hepatology Communications |
ISSN: | 2471-254X |
Popis: | We evaluated the effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) genotype 1 and SOF/velpatasvir (SOF/VEL) for all genotypes among people who inject drugs (PWID) and those not injecting drugs and who were on or off opioid agonist therapy (OAT). Study participants comprised a population‐based cohort in British Columbia, Canada. The British Columbia Hepatitis Testers Cohort includes data on individuals tested for HCV from 1990 to 2016 that are integrated with medical visits, hospitalization, and prescription drug data. We classified study participants as off OAT/recent injection drug use (off‐OAT/RIDU), off OAT/past IDU (off‐OAT/PIDU), off OAT/no IDU (off‐OAT/NIDU), on OAT/IDU (on‐OAT/IDU), and on OAT/no IDU (on‐OAT/NIDU). We assessed sustained virologic response (SVR) 10 weeks after HCV treatment among study groups treated with LDV/SOF or SOF/VEL until January 13, 2018. Analysis included 5,283 eligible participants: 390 off‐OAT/RIDU, 598 off‐OAT/PIDU, 3,515 off‐OAT/NIDU, 609 on‐OAT/IDU, and 171 on‐OAT/NIDU. The majority were male patients (64%‐74%) and aged ≥50 years (58%‐85%). The SVRs for off‐OAT/RIDU, off‐OAT/PIDU, off‐OAT/NIDU, on‐OAT/IDU, and on‐OAT/NIDU were 91% (355/390), 95% (570/598), 96% (3,360/3,515), 93% (567/609), and 95% (163/171), respectively. Among those with no SVR, 14 individuals died while on treatment or before SVR assessment, including 4 from illicit drug overdose. In the overall multivariable model, off‐OAT/RIDU, on‐OAT/IDU, male sex, cirrhosis, treatment duration |
Databáze: | OpenAIRE |
Externí odkaz: |